Catalent Capabilities Update September 2026: ADC

Antibody-drug conjugates demand a complex coordination of small- and large-molecule expertise, and finding a single partner who can characterize every component is a persistent challenge for developers. In this presentation, Dominic Yeo, Field Scientist with Catalent Biologics Analytical Services, introduces the company's dedicated Kansas City analytical facility and its approach to supporting ADC programs at any stage — from screening antibodies against their targets through clinical development. Backed by more than 30 years of experience, over 300 programs supported, and a 90% client return rate, the analytics-only site offers modality-agnostic capabilities across mAbs, ADCs, bispecifics, cell and gene therapies, and more.

The session details how Catalent supports each element of the ADC: formulation and buffer-exchange services, robust stability testing across more than 31,000 square feet of validated chambers, and conjugation support up to two-gram scale across multiple technologies. Yeo walks through the analytical toolkit available for characterizing the antibody, linker-payload, and intact conjugate — including LC-MS/MS, charge-variant and higher-order structure analysis, cytotoxicity and internalization assays, binding kinetics, thermal stability by DSC/DSF, glycan analysis, and residual testing. Critically, he explains how consolidating analytics under a single partner streamlines the path to IND and BLA submission, giving sponsors one consistent, coherent data set regardless of how many CDMOs handle manufacturing.